Compass Therapeutics drops sharply as trial crossover complicates survival data in bile duct cancer patients

Compass Therapeutics Inc. CMPX shares are tumbling on Monday as the company announced results from its COMPANION-002 study, ...

Compass Therapeutics Touts “Stunning” PFS Win in COMPANION-002 as Crossover Muddy OS Data

Compass Therapeutics (NASDAQ:CMPX) executives highlighted what CEO and Vice Chair Dr. Thomas Schuetz called “absolutely ...
Targeted Oncology

Tovecimig Improves PFS, But Misses OS End Point in Biliary Tract Cancer

Tovecimig (CTX-009) in combination with paclitaxel significantly improved progression-free survival (PFS), but not overall ...
Techno-Science.net on MSN

Beef or chicken? A study challenges a common belief

A common belief in the food domain is that red meat is harmful to metabolism, unlike white meat. However, a recent study ...
The Manila Times

Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus paclitaxel alone in the key secondary endpoint of ...